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INTRODUCTION
A shorter time to reperfusion is beneficial in treating pa-
tients with fibrinolytic therapy for acute ST-segment eleva-
tion myocardial infarction (STEMI) (1-4). In contrast, there
is some controversy regarding the relationship between mor-
tality and time to reperfusion with primary percutaneous
coronary intervention (PCI), although the American College
of Cardiology/American Heart Association (ACC/AHA)
guidelines recommend that the door-to-balloon time (or
medical contact-to-balloon) for PCI should be kept under
90 min (5). Some studies have shown that delays in symp-
tom onset-to-balloon time (6-9) or door-to-balloon time
adversely affects the prognosis in patients with STEMI (10,
11). However, in other studies, there was no significant dif-
ference in clinical outcomes according to the time to reper-
fusion (4, 12). In addition, because the initial treatment delay
is an important quality indicator of the treatment for such
patients, it is worthwhile to investigate how many cases are
performed according to the guidelines. Therefore, the aim
of this study was to evaluate the current status of delay in
the time to reperfusion during primary PCI and its impact
on patient mortality one month later using data from the
Korea Acute Myocardial Infarction Registry (KAMIR), the
first nationwide multicenter registry of acute MI in Korea.
We also tried to define the subgroups that were mostly influ-
enced by treatment delay. 
MATERIALS AND METHODS
Study design and subjects
A cohort of patients with STEMI who underwent prima-
ry PCI was selected from the KAMIR, which is a nation-
wide study for acute myocardial infarction in Korea. Between
November 2005 and January 2007, 5,069 patients at 41 hos-
pitals were registered.
Patients were eligible for enrollment if they had STEMI,
presented within 12 hr after symptom onset, and were treat-
ed with primary PCI, and if they had completed a 30-day
clinical follow-up at the analysis time point. The following
patients were excluded sequentially: patients without ST
elevation or left bundle branch block on the first electrocar-
diogram (n=2,076), those with cardiogenic shock (n=137),
those with unknown time of symptom onset or missing data
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The Impact of Initial Treatment Delay Using Primary Angioplasty on
Mortality among Patients with Acute Myocardial Infarction: from the
Korea Acute Myocardial Infarction Registry
The impact of treatment delays to reperfusion on patient mortality after primary
percutaneous coronary intervention (PCI) for ST elevation myocardial infarction
(STEMI) is controversial. We analyzed 5,069 patients included in the Korea Acute
Myocardial Infarction Registry (KAMIR) between November 2005 and January
2007. We selected 1,416 patients who presented within 12 hr of symptom onset
and who were treated with primary PCI. The overall mortality at one month was
4.4%. The medians of door-to-balloon time, symptom onset-to-balloon time, and
symptom onset-to-door time were 90 (interquartile range, 65-136), 274 (185-442),
and 163 min (90-285), respectively. One-month mortality was not increased signifi-
cantly with any increasing delay in door-to-balloon time (4.3% for ≤ ≤90 min, 4.4%
for >90 min; p=0.94), symptom onset-to-balloon time (3.9% for ≤ ≤240 min, 4.8%
for >240 min; p=0.41), and symptom onset-to-door time (3.3% for ≤ ≤120 min, 5.0%
for >120 min; p=0.13). These time variables had no impact on one-month mortality
in any subgroup. Thus, this first nationwide registry data in Korea showed a good
result of primary PCI, and the patient prognosis may not depend on the initial treat-
ment delay using the current protocols.
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Accepted : 20 September 2007(n=442), and those with symptom onset-to-door time ≥12
hr (n=421). Among the 5,069 patients, 1,993 patients had
reperfusion eligible for STEMI and 1,800 (90.3%) received
reperfusion therapy. Reperfusion therapy with primary PCI
was performed in 1,530 patients (85.0% of 1,800) and with
thrombolysis in 270 (15.0% of 1,800). Patients who did not
undergo the one-month follow-up were excluded (n=114).
We finally included 1,416 patients with STEMI who were
treated with primary PCI and who completed the one-month
follow-up (Fig. 1).
Demographic and clinical characteristics recorded were
gender, age, and medical history. The latter included any
history of smoking, dyslipidemia, hypertension, diabetes
mellitus, chronic renal insufficiency, stroke, ischemic heart
disease, family history of coronary artery disease, previous
PCI, previous coronary artery bypass graft surgery, or any
past regular medication. The presentation characteristics
included symptoms at admission, systolic and diastolic blood
pressure, heart rate and rhythm, Killip classification, the results
of the diagnostic electrocardiography (ECG), and ischemic
location on ECG.
Definitions and outcomes measures
Time variables were defined as follows: door-to-balloon
time was the time from arrival in the emergency department
until initial balloon inflation; symptom onset-to-balloon
time was the time from the onset of symptoms until the first
balloon inflation; and symptom onset-to-door time was the
time from the onset of symptoms until arrival in the emer-
gency department. Patients were divided into two groups
according to door-to-balloon time (≤90 min and >90 min),
symptom onset-to-balloon time (≤240 min and >240 min),
and symptom onset-to-door time (≤120 min and >120
min), respectively. 
The main outcomes were mortality at one month and major
cardiovascular adverse events (MACEs). MACEs included
death, reinfarction, and target vessel revascularization.
Statistical analysis
SPSS for Windows (version 12.0; SPSS Inc., Chicago, IL,
U.S.A.) was used for all analyses. Continuous data are express-
ed as the mean±SD or as the median and interquartile range
(25th and 75th percentiles); categorical data were expressed
as percentages. Statistical comparisons of baseline, angio-
graphic, and outcome variables were performed for categori-
cal variables using the Chi-squared test or Fisher’s exact test
(if the expected value of the variable was <5 in at least one
group). Student’s t test was applied to continuous variables.
p<0.05 was considered statistically significant. Multiple
logistic regression analysis was performed to assess the rela-
tion between predictor variables and one-month mortality.
RESULTS
Baseline characteristics
Medians of times to treatment were as follows: door-to-
balloon time, 90 min (interquartile range, 65-136 min); symp-
tom onset-to-balloon time, 274 min (185-442); and symp-
tom onset-to-door time, 163 min (90-285). Of all patients,
36% presented to the hospital within 120 min of symptom
onset. Door-to-balloon time was 90 min or less in 51% of
patients and 42% of patients were reperfused within 240 min
of symptom onset. A post-PCI thrombolysis in myocardial
infarction (TIMI) grade 3 flow was achieved in 92.8% of the
patients.
Demographic, clinical, and angiographic characteristics
according to door-to-balloon time, symptom onset-to-bal-
loon time, and symptom onset-to-door time are presented
in Table 1. Patients with door-to-balloon times >90 min had
hypertension and Killip class ≥3 more frequently than did
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Fig. 1. Selection criteria.
Without ST-elevation
of LBBB on ECG
N=2,076
Cardiogenic shock
N=137
KAMIR
N=5,069
AMI patients
41 Hospitals
With unknown time of symptom
onset or missing data
N=442
Reperfusion therapy
with thrombolysis
N=270
1-month follow-up loss
N=114
Study Population
1,416 patients
41 Hospitals
Time to presentation ≥12 hr
N=421
Conservative treatment
N=193
1,993
Reperfusion
eligible
STEMI patients
Reperfusion therapy
with primary PCI
N=1,530patients with door-to-balloon times ≤90 min. The preva-
lences of older patients, women, having diabetes mellitus,
hypertension, Killip class ≥3, multivessel disease, and lower
left ventricular ejection fraction were higher in patients with
longer symptom onset-to-balloon times than in those with
shorter symptom onset-to-balloon times. Patients with longer
symptom onset-to-door times tended to be older, to be women,
and to have anterior infarction more frequently and lower left
ventricular ejection fraction than did patients with shorter
symptom onset-to-door times.
Of the patients enrolled in the study, 262 patients (18.5%)
were treated with glycoprotein IIb/IIIa inhibitors. Triple
antiplatelet agents with aspirin, clopidogrel, and cilostazol
were prescribed in 598 patients (42.1%). One-hundred and
twenty-two patients (8.6%) with antiplatelet use before the
index MI were not statistically different in mortality (5.7%
vs. 4.3%, p=0.44) and MACE (7.4% vs. 5.5%, p=0.39) com-
pared with those without antiplatelet use. Sixty-three patients
(4.5%) were treated with statin before the index MI.
Clinical outcomes by time variables
Sixty-two patients (4.4%) had died by one month after
the procedure. Table 2 shows the association between treat-
ment delay and clinical outcomes. Mortality at this point
did not increase significantly with increasing delay in door-
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Door-to-balloon time
p ≤90 
(n=715)
>90 
(n=701)
Symptom onset-to-balloon time
p ≤240 
(n=597)
>240 
(n=819)
Symptom onset-to-door time
p ≤120 
(n=515)
>120 
(n=901)
Clinical variables
Age (yr) 60.8±12.9 61.8±12.9 0.14 59.0±12.9 62.9±12.8 <0.01 58.2±13.0 63.0±12.6 <0.01
Age >70 yr (%) 29.2 31.7 0.32 23.5 35.5 <0.01 21.2 35.7 <0.01
Women (%) 23.8 26.3 0.28 19.1 29.3 <0.01 18.5 28.7 <0.01
Diabetes mellitus (%) 21.6 25.9 0.06 20.7 25.9 0.03 22.3 24.5 0.34
Hypertension (%) 41.9 49.3 <0.01 40.8 49.0 <0.01 42.7 47.2 0.10
Prior MI (%) 2.4 3.1 0.38 2.5 2.9 0.64 3.7 2.2 0.10
Prior PCI (%) 3.6 3.1 0.61 3.9 3.1 0.41 4.3 2.9 0.17
Anterior infarction (%) 53.7 52.9 0.77 51.7 54.4 0.31 49.7 55.3 0.04
Killip class ≥3 (%) 5.5 11.0 <0.01 6.5 9.5 0.04 8.5 8.1 0.79
Serum Cr ≥1.5 mg/dL (%) 6.0 8.3 0.10 6.1 8.0 0.17 7.3 7.1 0.93
Angiographic/procedural variables
Pre-PCI TIMI 0-1 flow (%) 73.8 68.8 0.05 72.9 70.2 0.28 72.3 70.8 0.56
Post-PCI TIMI 3 flow (%) 93.3 92.2 0.43 94.0 91.9 0.13 93.5 92.4 0.46
Multivessel diseases (%) 47.3 52.6 0.05 46.3 52.5 0.02 48.6 50.6 0.47
Ejection fraction (%) 51.5±11.6 50.8±11.7 0.26 52.3±11.4 50.3±11.8 <0.01 52.4±11.1 50.4±11.9 <0.01
Table 1. Baseline patient characteristics by time variables
MI, myocardial infarction; PCI, percutaneous coronary intervention; Cr, creatinine; TIMI, thrombolysis in myocardial infarction.
Door-to-balloon time (min)
p ≤90 
(n=715)
>90 
(n=701)
Symptom onset-to-balloon time (min)
p ≤240 
(n=597)
>240 
(n=819)
Symptom onset-to-door time (min)
p ≤120 
(n=515)
>120 
(n=901)
Mortality (%) 4.3 4.4 0.94 3.9 4.8 0.41 3.3 5.0 0.13
MACEs (%) 5.5 5.8 0.75 4.5 6.5 0.12 4.5 6.3 0.15
Follow-up LVEF (%) 54.3±10.9 54.0±11.7 0.80 54.7±10.1 53.6±12.2 0.38 55.4±10.1 53.4±11.8 0.13
Table 2. One-month outcomes by time variables
MACEs, major adverse cardiovascular events; LVEF, left ventricular ejection fraction.
Fig. 2. Kaplan-meier estimates of cumulative survival stratified by
door-to-balloon time.
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>90 minto-balloon time (4.3% for ≤90 min vs. 4.4% for >90 min;
p=0.94), symptom onset-to-balloon time (3.9% for ≤240
min vs. 4.8% for >240 min; p=0.41), and symptom onset-
to-door time (3.3% for ≤120 min vs. 5.0% for >120 min;
p=0.13) (Fig. 2). The rate of MACEs at one month was not
significantly different according to door-to-balloon time,
symptom onset-to-balloon time, or symptom onset-to-door
time. When patients were divided into 4 groups according to
door-to-balloon time (≤90, 90-120, 120-180, ≥180 min)
or symptom onset-to-balloon time (≤2, 2-4, 4-6, ≥6 hr),
incremental delays in reperfusion appeared to have little effect
on the one-month mortality and MACE rate (Fig. 3, 4). The
left ventricular ejection fraction at the one-month follow-up
was also similar between the early reperfused and late reper-
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Fig. 3. The one-month mortality (A) and MACEs (B) stratified by door-to-balloon time.
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Fig. 4. The one-month mortality (A) and MACEs (B) stratified by symptom onset-to-balloon time.
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Mortality (n=62) p MACEs (n=80) p
Clinical variables
Age >70 yr 37/431 (8.6%) <0.01 41/431 (9.5%) <0.01
Women 27/354 (7.6%) <0.01 28/354 (7.9%) 0.03
Diabetes mellitus 16/331 (4.8%) 0.58 21/331 (6.3%) 0.49
Hypertension 30/637 (4.7%) 0.48 39/637 (6.1%) 0.42
Prior myocardial infarction 3/39 (7.7%) 0.31 6/39 (15.4%) <0.01
Prior PCI 2/48 (4.2%) 0.94 4/48 (8.3%) 0.41
Anterior infarction 35/750 (4.7%) 0.61 46/750 (6.1%) 0.44
Killip classification ≥3 20/115 (17.4%) <0.01 21/115 (18.3%) <0.01
Serum creatinine ≥1.5 mg/dL 14/101 (13.9%) <0.01 17/101 (16.8%) <0.01
Ejection fraction ≤40% 25/232 (10.8%) <0.01 29/232 (12.5%) <0.01
Angiographic/procedural variables
Pre-PCI TIMI 0-1 flow 48/994 (4.8%) 0.08 58/994 (5.8%) 0.43
Post-PCI TIMI 0-2 flow 15/100 (15.0%) <0.01 16/100 (16.0%) <0.01
Multivessel diseases 46/702 (6.6%) <0.01 63/702 (9.0%) <0.01
Table 3. Univariate predictors of one-month mortality and MACEs
MACEs, major adverse cardiovascular events; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.fused patients regarding door-to-balloon time, symptom
onset-to-balloon time, and symptom onset-to-door time.
Predictors of one-month clinical outcomes
Applying univariate analysis, various clinical and angio-
graphic or procedural variables were significantly associated
with one-month mortality and MACEs (Table 3). In multi-
variate analysis, old age (>70 yr), Killip class ≥3, serum
creatinine ≥1.5 mg/dL, post-PCI TIMI flow grades of 0-2,
and left ventricular dysfunction (ejection fraction ≤40%)
were significantly associated with mortality. From the multi-
variate analysis, Killip class ≥3, serum creatinine ≥1.5 mg/
dL, left ventricular dysfunction (ejection fraction ≤40%),
and multivessel disease were independent predictors for
MACEs (Table 4).
Clinical outcomes by time variables in subgroups
We performed subgroup analysis to identify those patients
with outcomes most influenced by treatment delay. Based
upon multivariate analysis for one-month mortality, we divid-
ed patients by age, serum creatinine, Killip classification,
left ventricular ejection fraction, and post-PCI TIMI flow
grade. Treatment delay was not significantly associated with
increased short-term mortality in any subgroup. Moreover,
among patients at high risk (age >70 yr, serum creatinine
≥1.5 mg/dL, Killip classification ≥3, left ventricular ejec-
tion fraction ≤40%, post-PCI TIMI flow grades 0-2), the
increase in door-to-balloon time, symptom onset-to-balloon
time, or symptom onset-to-door time did not correlate with
one-month mortality; nor were there any such associations
among low-risk patients (Table 5).
DISCUSSION
Primary PCI was the preferred reperfusion strategy in this
registry, and more than half of the patients underwent pri-
mary PCI within the time window recommended in the
guidelines. The one-month mortality was 4.4% and was
not increased significantly with increasing delay in door-to-
balloon time, symptom onset-to-balloon time, or symptom
onset-to-door time. These time variables had no impact on
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Odds ratio of mortality
(95% confidence interval)
Odds ratio of MACEs
(95% confidence interval)
p p
Age >70 yr 2.43 (1.12-5.23) 0.02 1.29 (0.68-2.43) 0.44
Women 1.34 (0.61-2.99) 0.47 0.85 (0.42-1.74) 0.66
Serum creatinine ≥1.5 3.53 (1.45-8.57) <0.01 2.76 (1.27-5.98) 0.01
Killip classification ≥3 3.65 (1.62-8.22) <0.01 2.56 (1.21-5.40) 0.01
LVEF ≤40% 8.02 (3.64-17.64) <0.01 4.77 (2.59-8.82) <0.01
Multivessel disease 2.16 (0.97-4.81) 0.06 3.64 (1.80-7.38) <0.01
Post-PCI TIMI flow 0-2 3.27 (1.26-8.48) 0.02 2.27 (0.97-5.24) 0.06
Table 4. Multivariate predictors of one-month mortality and MACEs
MACEs, major adverse cardiovascular events; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; TIMI, thrombolysis in
myocardial infarction.
Door-to-balloon time
p ≤90 min 
(%)
>90 min 
(%)
Symptom onset-to-balloon time
p ≤240 min 
(%)
>240 min 
(%)
Symptom onset-to-door time
p ≤120 min 
(%)
>120 min 
(%)
Age >70 yr (n=431) 24/209 (11.5) 13/222 (5.9) 0.06 12/140 (8.6) 25/291 (8.6) 0.99 11/109 (10.1) 26/322 (8.1) 0.52
Age ≤70 yr (n=985) 7/506 (1.4) 18/479 (3.8) 0.06 11/457 (2.4) 14/528 (2.7) 0.81 6/406 (1.5) 19/579 (3.3) 0.08
Serum Cr ≥1.5 mg/dL (n=101) 9/43 (20.9) 5/58 (8.6) 0.08 5/36 (13.9) 9/65 (13.8) 0.99 2/37 (5.4) 12/64 (18.8) 0.06
Serum Cr <1.5 mg/dL (n=1,306) 21/668 (3.1) 26/638 (4.1) 0.37 18/557 (3.2) 29/749 (3.9) 0.54 15/473 (3.2) 32/833 (3.8) 0.53
Killip class 3-4 (n=115) 5/39 (12.8) 15/76 (19.7) 0.35 6/38 (15.8) 14/77 (18.2) 0.75 6/43 (14.0) 14/72 (19.4) 0.45
Killip class 1-2 (n=1,281) 26/666 (3.9) 16/615 (2.6) 0.19 17/549 (3.1) 25/732 (3.4) 0.75 11/463 (2.4) 31/818 (3.8) 0.17
LVEF ≤40% (n=232) 12/106 (11.3) 13/126 (10.3) 0.81 9/72 (12.5) 16/160 (10.0) 0.57 7/65 (10.8) 18/167 (10.8) 0.99
LVEF >40% (n=1,045) 6/543 (1.1) 4/502 (0.8) 0.61 0/454 (0) 10/591 (1.7) 0.06 0/392 (0) 10/653 (1.5) 0.06
Post-PCI TIMI <3 (n=100) 5/47 (10.6) 10/53 (18.9) 0.25 6/35 (17.1) 9/65 (13.8) 0.66 5/33 (15.2) 10/67 (14.9) 0.98
Post-PCI TIMI 3 (n=1,286) 26/657 (4.0) 18/629 (2.9) 0.28 15/549 (2.7) 29/737 (3.9) 0.24 10/472 (2.1) 34/814 (4.2) 0.06
High risk* (n=682) 29/318 (9.1) 23/364 (6.3) 0.17 19/228 (8.3) 33/454 (7.3) 0.62 14/199 (7.0) 38/483 (7.9) 0.71
Low risk (n=734) 2/397 (0.5) 8/337 (2.4) 0.06 4/369 (1.1) 6/365 (1.6) 0.51 3/316 (0.9) 7/418 (1.7) 0.401
Table 5. One-month mortality by time variables in patients subsets
*High risk: Age >70 yr; serum creatinine ≥1.5 mg/dL; Killip class ≥3; LVEF ≤40% or post-PCI TIMI <grade 3.
Cr, creatinine; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.one-month mortality in any subgroup.
Among 5,069 patients registered in the KAMIR between
November 2005 and January 2007, 1,993 patients had
STEMI and was eligible for reperfusion. Reperfusion thera-
py was performed over 90% of these patients, and only a
minority received conservative treatment. The rate of receiv-
ing reperfusion therapy among these eligible patients with
STEMI in the KAMIR seems to be higher than in previous
data. From data of the National Registry of Myocardial Infarc-
tion (NRMI) in the U.S.A., one-half of the patients with
STEMI who were eligible for reperfusion received reperfu-
sion therapy (13). Notably, primary PCI was the overwhelm-
ingly preferred reperfusion strategy in this registry. Among
those patients receiving reperfusion therapy, primary PCI
was performed in 85%. This rate of primary PCI is much
higher than results from other countries, which showed that
primary PCI was performed in one-fourth to one-third (13,
14). In the KAMIR, the incidence of post-PCI TIMI grade
3 flow was also very high at 92.8%. This is higher than that
reported in studies from the U.S.A. (15, 16). Moreover, the
median door-to-balloon time was 90 min, which means that
one-half of patients undergoing primary PCI received reper-
fusion in the recommended time in this registry. Recently
published studies in U.S.A. showed that fewer than one-half
of patients with STEMI received reperfusion in the recom-
mended door-to-balloon time, and the mean door-to-bal-
loon time was 108.0 min (95% CI, 106.5-109.4 min) (17).
The growing interest in primary PCI and easy accessibility
to the large-volume hospitals capable of performing prima-
ry PCI, most of which participated in the KAMIR, may
account for the higher performance of primary PCI in this
registry than in those reports.
In our study, the overall one-month mortality was 4.4%.
This rate is similar to that reported in the NRMI in the
U.S.A. (11). Our study found that old age, high Killip class,
left ventricular dysfunction, elevated serum creatinine, and
post-PCI TIMI flow grades of 0-2 were independent predic-
tors of one-month mortality after primary PCI. These risk
factors also predicted the mortality consistently with several
other studies (18-20).
Despite the notion the efficacy of fibrinolytic therapy is
largely dependent on time to reperfusion (1-4, 21, 22), sev-
eral studies suggest that time to reperfusion may be less im-
portant in PCI (10, 11). Myocardial salvage has been found
to be related to time from symptom onset to fibrinolytic
therapy but was not related to time from symptom onset to
ballooning (12, 23). In some studies, delays in door-to-bal-
loon time have an impact on late survival rates only in high-
risk patients and in patients presenting early after the onset
of symptoms (19). In our study, door-to-balloon time and
symptom onset-to-balloon time also appeared to have little
effect on one-month mortality and MACEs. Moreover, we
could not identify any subgroups that were influenced by
treatment delay.
There are several possible reasons for the poor relationship
between early mortality and time variables of treatment delay
in primary PCI, unlikely in fibrinolytic therapy. First, with
thrombolytic therapy, the successful reperfusion rate decreas-
es dramatically with delay to reperfusion (24, 25), whereas
the procedural success rate of primary PCI remains high
regardless of this (6, 12). Second, higher TIMI grade 3 flow
was achieved even in the high-risk patients, regardless of
time to reperfusion in patients with primary PCI (6, 12).
Third, death from myocardial rupture increases progressive-
ly with increasing time to treatment with thrombolytic
therapy (26) but is uncommon following primary PCI (27).
Fourth, the assessment of the time of symptom onset is often
difficult because of patient’s reporting error. Patients fre-
quently are unsure of the exact time of symptom onset and
usually give an estimate. Finally, the patients with high risk
factors are more prone to die before they arrive at hospital
and are therefore selected out from this registry. It is likely
that the exclusion of these patients decreased the effect of
symptom onset-to-door time on mortality.
Because time to reperfusion did not have a major impact
on clinical outcomes in our study, in patients presenting to
local hospitals without interventional facilities, a transfer to
interventional centers for primary PCI may be considered
despite additional treatment delays. Several randomized tri-
als suggest that this implication may be true (28-30). How-
ever, we would like to emphasize that these data do not defend
treatment delay without a justifiable cause. We consider that
all efforts should be made to shorten time to reperfusion fol-
lowing the ACC/AHA guidelines, which were based on six
randomized controlled trials according to the Zwolle group
meta-analysis (5).
Our study had several limitations. First, although the
KAMIR is the nationwide multicenter trial in Korea, the
number of patients, especially in this study cohort, was rela-
tively small. Therefore, the statistical power to detect differ-
ences in mortality between time variable groups was limited.
Second, we included only 1,416 patients from 5,069. More-
over, 114 patients (7.5%) of 1,530 who had been treated
with primary PCI did not undergo the one-month follow-up.
This may influence the one-month mortality and MACE
rate. Third, as mentioned previously, only large hospitals
that were capable of performing primary PCI participated
in the KAMIR. Consequently, these subsets may not be
representative of the entire cohort and this could have intro-
duced selection bias. Finally, techniques of primary PCI vary
with hospitals, which might have influenced the outcomes
of primary PCI, and in turn, the results of our study.
In conclusion, this first nationwide registry of acute myocar-
dial infarction in Korea showed a good result of primary PCI.
The one-month mortality was not associated with initial
time variables to reperfusion, suggesting that patient prog-
nosis may not depend on the initial treatment delay with
the current practice of primary PCI. However, further stud-
362 Y.B. Song, J.-Y. Hahn, H.-C. Gwon, et al.ies are warranted to validate our observations.
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